SCHEMBL15480596

SCHEMBL15480596

Cc1cccc(S(=O)(=O)N(C)c2ccc(C(=O)NO)cc2)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.57
LMNA P02545 3/20 0.57
HTT P42858 2/20 0.57
SIRT2 Q8IXJ6 4/20 0.56
CYP3A4 P08684 1/20 0.55
CYP2D6 P10635 1/20 0.55
CYP2C9 P11712 1/20 0.55
CYP2C19 P33261 1/20 0.55
HDAC8 Q9BY41 4/20 0.52
HDAC6 Q9UBN7 4/20 0.52
HDAC3 O15379 3/20 0.52
HDAC11 Q96DB2 3/20 0.52
TSHR P16473 2/20 0.52
GBA1 P04062 2/20 0.52
ALDH1A1 P00352 1/20 0.52
MAPK1 P28482 1/20 0.52
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
GAA P10253 1/20 0.50
HDAC4 P56524 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15482268 0.87 LMNA (0.61) SMN1; SMN2LMNAHTTSIRT2HDAC8
SCHEMBL15480600 0.85 GBA1 (0.64) SMN1; SMN2LMNAHTTHDAC8TSHR
SCHEMBL15480590 0.83 MAPT (0.68) SMN1; SMN2LMNAHTTHDAC6ALDH1A1
SCHEMBL18407541 0.83 HDAC8 (0.74) SMN1; SMN2LMNAHTTSIRT2HDAC8
SCHEMBL15480612 0.81 NPC1 (0.67) SMN1; SMN2LMNAHTTSIRT2HDAC8
SCHEMBL15482262 0.79 HDAC6 (0.64) SMN1; SMN2LMNAHTTHDAC8HDAC6
SCHEMBL18088392 0.78 CA12 (0.67) SMN1; SMN2LMNAHTTCYP3A4CYP2C9
SCHEMBL15480632 0.78 MAPT (0.59) SMN1; SMN2LMNAHTTHDAC6ALDH1A1
SCHEMBL15480601 0.78 SIRT2 (0.56) SMN1; SMN2LMNAHTTSIRT2HDAC6
SCHEMBL15482278 0.78 LMNA (0.57) SMN1; SMN2LMNAHTTHDAC8HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170020874-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS CERENO SCIENT AB (SE) 2017-01-26 US disclosed
US-20140051716-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS CERENO SCIENTIFIC AB 2014-02-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140051716-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS HDAC3, HDAC1, HDAC2 SMN1; SMN2 2901/4885LMNA 489/4885HTT 546/4885
US-20170020874-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS HDAC3, HDAC1, HDAC2 SMN1; SMN2 2901/4885LMNA 489/4885HTT 546/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.